Gemphire Therapeutics Inc (GEMP.OQ)
14 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|63||2014||Chairman of the Board, Chief Scientific Officer|
|64||2017||Interim President, Interim Chief Executive Officer, Director|
|49||2014||President, Chief Executive Officer, Director|
|56||2015||Chief Financial Officer|
|49||2016||Chief Medical Officer|
- BRIEF-Gemphire Therapeutics reports qtrly loss of $0.82/shr
- BRIEF-Gemphire announces plans to advance gemcabene into phase 3 clinical development
- BRIEF-Gemphire Therapeutics Inc files mixed shelf of up to $175 million - SEC filing
- BRIEF-Gemphire Therapeutics Inc posts Q2 net loss $0.99/shr
- BRIEF-Gemphire announces top-line data from royal-1 phase 2b clinical trial in hypercholesterolemic patients